Fate Therapeutics
FATE
1,46 €
Share price
9.87%
Change (1 day)
-59.19%
Change (1 year)
Categories
Fate Therapeutics (FATE) - Total debt
Total debt on the balance sheet as of March 2025 : €72.92 Million
According to Fate Therapeutics 's latest financial reports the company's total debt is €72.92 Million. A company’s total debt is the sum of all current and non-current debts.
Fate Therapeutics - Total debt on balance sheet (from 2012 to 2025)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2024-12-31 | €81.93 M | -12.52% |
| 2023-12-31 | €93.65 M | -8.12% |
| 2022-12-31 | €0.10 B | 0.54% |
| 2021-12-31 | €0.10 B | 28.16% |
| 2020-12-31 | €79.1 M | 229.1% |
| 2019-12-31 | €24.03 M | 84.75% |
| 2018-12-31 | €13.01 M | 5.42% |
| 2017-12-31 | €12.34 M | 21.46% |
| 2016-12-31 | €10.16 M | -39.08% |
| 2015-12-31 | €16.68 M | 3.46% |
| 2014-12-31 | €16.12 M | 1185.51% |
| 2013-12-31 | €1.25 M | -54.83% |
| 2012-12-31 | €2.77 M | -25.48% |
| 2011-12-31 | €3.72 M |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 Sarepta Therapeutics
SRPT | €1.17 B | 1,512.58% | 🇺🇸 USA |
 Becton Dickinson BDX | €16.86 B | 23,025.20% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | €0.34 B | 367.56% | 🇺🇸 USA |
 Avidity Biosciences RNA | €5.22 M | -92.83% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | €0.39 B | 437.03% | 🇺🇸 USA |